PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Efficacy And Safety Of PF-00885706 For The Relief Of Symptoms In Subjects With Gastro-esophageal Reflux Disease (GERD)
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- First Posted Date
- 2008-08-08
- Last Posted Date
- 2011-07-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 81
- Registration Number
- NCT00730665
- Locations
- 🇪🇸
Pfizer Investigational Site, Sevilla, Spain
A Phase I, Healthy Volunteer Positron Emission Tomography Study
- Conditions
- Healthy
- Interventions
- Other: Positron Emission tomographyDrug: PET Scan with PF-03654746
- First Posted Date
- 2008-08-08
- Last Posted Date
- 2019-03-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 10
- Registration Number
- NCT00730990
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors
- Conditions
- Advanced CancerAdvanced Solid Tumors
- Interventions
- Drug: CP-751,871Drug: Sunitinib
- First Posted Date
- 2008-08-08
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 45
- Registration Number
- NCT00729833
- Locations
- 🇺🇸
Pfizer Investigational Site, San Antonio, Texas, United States
Assessing Prevalence Of Beta Lactamase Production From Clinical Isolates Of Hospitalized Patients And Comparison Of Antibiotic Susceptibility Patterns
- Conditions
- Infection
- First Posted Date
- 2008-08-06
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2039
- Registration Number
- NCT00728624
- Locations
- 🇮🇳
Pfizer Investigational Site, New Delhi, India
A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer Patients
- Conditions
- Advanced Malignant Solid Tumors
- Interventions
- Drug: PF-00299804
- First Posted Date
- 2008-08-05
- Last Posted Date
- 2017-08-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT00728468
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States
A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks
- Conditions
- Neoplasm MetastasisCarcinoma, Non-Small Cell
- Interventions
- Drug: PF-00299804
- First Posted Date
- 2008-08-05
- Last Posted Date
- 2024-04-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 74
- Registration Number
- NCT00728390
- Locations
- 🇪🇸
Pfizer Investigational Site, Madrid, Spain
A Study In Patients With Advanced Solid Tumor
- First Posted Date
- 2008-08-01
- Last Posted Date
- 2012-05-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 6
- Registration Number
- NCT00726752
- Locations
- 🇯🇵
Pfizer Investigational Site, Kobe-shi, Hyogo-ken, Japan
An Open-Label Safety Study Of DIC075V (Intravenous Diclofenac Sodium) In Patients With Acute Post-Operative Pain
- Conditions
- Pain, Postoperative
- Interventions
- Drug: DIC075V (intravenous diclofenac sodium)
- First Posted Date
- 2008-07-31
- Last Posted Date
- 2021-10-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1050
- Registration Number
- NCT00726388
- Locations
- 🇺🇸
Staten Island University Hospital, Staten Island, New York, United States
🇺🇸UPMC-St. Margaret's Hospital, Pittsburgh, Pennsylvania, United States
🇺🇸Tulane Univ. Medical Center, New Orleans, Louisiana, United States
Study Evaluating The Safety And Tolerability Of Combination Therapy Inotuzumab Ozogamicin (CMC-544) And Rituximab
- Conditions
- Lymphoma, B-Cell
- Interventions
- Drug: Inotuzumab Ozogamicin (CMC-544)Drug: Rituximab (Rituxan)
- First Posted Date
- 2008-07-30
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 10
- Registration Number
- NCT00724971
- Locations
- 🇯🇵
Nagoya Daini Red Cross Hospital, Aichi, Japan
🇯🇵Tokai University Hospital, Kanagawa, Japan
🇯🇵National Cancer Center Hospital, Tokyo, Japan
PF-04191834 Single Dose Bronchodilatory Study In Asthma.
- First Posted Date
- 2008-07-28
- Last Posted Date
- 2013-02-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 15
- Registration Number
- NCT00723021
- Locations
- 🇺🇸
Pfizer Investigational Site, Omaha, Nebraska, United States